Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer (multiple letters) [1]

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5967-5969

  Varterasian, Mary ^b   Fingert, Howard ^b   Agin, Marilyn ^b   Meyer, Mark ^b   Cooney, Matthew ^a   Radivoyevitch, Tomas ^a   Dowlati, Afshin ^a   Overmoyer, Beth ^a   Levitan, Nathan ^a   Robertson, Kelly ^a   Remick, Scot C ^a   Stambler, Bruce S ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE School of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; COMBRETASTATIN A4 PHOSPHATE; COMBRETASTATIN B1; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ADVANCED CANCER; CLINICAL TRIAL; ELECTROCARDIOGRAPHY MONITORING; HEART RATE VARIABILITY; HUMAN; LETTER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QTC INTERVAL; TUMOR BLOOD FLOW; VOLUNTEER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS, PHASE I; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; NEOPLASMS; SAFETY; STILBENES;

EID: 4444306383     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0534     Document Type: Letter

References (0)